Vistagen Therapeutics' positive earnings report, beating estimates by 26.67% and showing revenue growth, typically would lead to a positive short-term impact on its stock price. However, considering the historical context where a previous earnings beat was followed by a significant share price drop, investor reaction could be mixed. The positive score reflects the immediate positive impact of beating earnings estimates, but investor caution is advised given past market reactions.